{"id":{"repo_id":"debrecen","oai_identifier":"oai:dea.lib.unideb.hu:2437/389175"},"canonical_url":"https://search.dev.ndltd.org/etd/debrecen/oai:dea.lib.unideb.hu:2437/389175","repository":{"repo_id":"debrecen","name":"University of Debrecen","base_url":"https://dea.lib.unideb.hu/server/oai/request"},"display":{"title":"Endocrine Effects of Cancer Chemotherapy","abstract":"This thesis explores the pharmacological effects of cancer chemotherapy on endocrine organs, emphasizing both therapeutic advantages and adverse effects. It categorizes chemotherapeutic agents based on their mechanisms of action and their impact on endocrine function, highlighting both intended hormonal modulation and unintended endocrine toxicities. The thesis adopts both a pharmacological and organ-specific approach, detailing how different drug classes—such as alkylating agents, antimetabolites, antitumor antibiotics, targeted therapies, and immune checkpoint inhibitors—affect the endocrine system. It examines chemotherapy-induced dysfunctions in key endocrine glands, including the hypothalamus-pituitary axis, thyroid, adrenal glands, gonads, and pancreas. Special attention is given to long-term endocrine complications in cancer survivors, particularly in the context of emerging therapies such as immune checkpoint inhibitors. Ultimately, the thesis underscores the importance of early detection, individualized management, and continued research to mitigate endocrine-related toxicities while optimizing cancer treatment outcomes.","abstract_html":"This thesis explores the pharmacological effects of cancer chemotherapy on endocrine organs, emphasizing both therapeutic advantages and adverse effects. It categorizes chemotherapeutic agents based on their mechanisms of action and their impact on endocrine function, highlighting both intended hormonal modulation and unintended endocrine toxicities. The thesis adopts both a pharmacological and organ-specific approach, detailing how different drug classes—such as alkylating agents, antimetabolites, antitumor antibiotics, targeted therapies, and immune checkpoint inhibitors—affect the endocrine system. It examines chemotherapy-induced dysfunctions in key endocrine glands, including the hypothalamus-pituitary axis, thyroid, adrenal glands, gonads, and pancreas. Special attention is given to long-term endocrine complications in cancer survivors, particularly in the context of emerging therapies such as immune checkpoint inhibitors. Ultimately, the thesis underscores the importance of early detection, individualized management, and continued research to mitigate endocrine-related toxicities while optimizing cancer treatment outcomes.","abstract_has_math":false,"creators":["Yang, Du Hyuk"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"DE--Általános Orvostudományi Kar","school":null,"contributors":[],"advisors":["Megyeri, Attila"],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-07-27T19:13:55Z","subjects":["Chemotherapy","Immune checkpoint inhibitors","Endocrine"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2437/389175","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Megyeri, Attila"]},{"key":"dc:contributor.department","label":"Department","values":["DE--Általános Orvostudományi Kar"]},{"key":"dc:creator","label":"Author","values":["Yang, Du Hyuk"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-04-15T08:37:12Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-04-15T08:37:12Z"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemotherapy","Immune checkpoint inhibitors","Endocrine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2437/389175"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This thesis explores the pharmacological effects of cancer chemotherapy on endocrine organs, emphasizing both therapeutic advantages and adverse effects. It categorizes chemotherapeutic agents based on their mechanisms of action and their impact on endocrine function, highlighting both intended hormonal modulation and unintended endocrine toxicities. The thesis adopts both a pharmacological and organ-specific approach, detailing how different drug classes—such as alkylating agents, antimetabolites, antitumor antibiotics, targeted therapies, and immune checkpoint inhibitors—affect the endocrine system. It examines chemotherapy-induced dysfunctions in key endocrine glands, including the hypothalamus-pituitary axis, thyroid, adrenal glands, gonads, and pancreas. Special attention is given to long-term endocrine complications in cancer survivors, particularly in the context of emerging therapies such as immune checkpoint inhibitors. Ultimately, the thesis underscores the importance of early detection, individualized management, and continued research to mitigate endocrine-related toxicities while optimizing cancer treatment outcomes."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["egységes, osztatlan"]},{"key":"dc:title","label":"Title","values":["Endocrine Effects of Cancer Chemotherapy"]}]}],"canonical_facts":{"dc:contributor.advisor":["Megyeri, Attila"],"dc:contributor.department":["DE--Általános Orvostudományi Kar"],"dc:creator":["Yang, Du Hyuk"],"dc:date.accessioned":["2025-04-15T08:37:12Z"],"dc:date.available":["2025-04-15T08:37:12Z"],"dc:description.abstract":["This thesis explores the pharmacological effects of cancer chemotherapy on endocrine organs, emphasizing both therapeutic advantages and adverse effects. It categorizes chemotherapeutic agents based on their mechanisms of action and their impact on endocrine function, highlighting both intended hormonal modulation and unintended endocrine toxicities. The thesis adopts both a pharmacological and organ-specific approach, detailing how different drug classes—such as alkylating agents, antimetabolites, antitumor antibiotics, targeted therapies, and immune checkpoint inhibitors—affect the endocrine system. It examines chemotherapy-induced dysfunctions in key endocrine glands, including the hypothalamus-pituitary axis, thyroid, adrenal glands, gonads, and pancreas. Special attention is given to long-term endocrine complications in cancer survivors, particularly in the context of emerging therapies such as immune checkpoint inhibitors. Ultimately, the thesis underscores the importance of early detection, individualized management, and continued research to mitigate endocrine-related toxicities while optimizing cancer treatment outcomes."],"dc:description.degree":["egységes, osztatlan"],"dc:identifier.uri":["https://hdl.handle.net/2437/389175"],"dc:language.iso":["en"],"dc:subject":["Chemotherapy","Immune checkpoint inhibitors","Endocrine"],"dc:title":["Endocrine Effects of Cancer Chemotherapy"]},"updated_at":"2026-07-27T19:13:55Z"}